118 related articles for article (PubMed ID: 35709177)
1. Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan.
Edahiro Y; Ochiai T; Hashimoto Y; Ichii M; Okatani T; Omura H; Nakajima K; Sasaki M; Ando J; Takaku T; Koike M; Izumiyama K; Hiraga J; Yano T; Usuki K; Ohtsuka E; Yokoyama K; Oyake T; Takahashi N; Nishida T; Nakao T; Fukuda Y; Akasaka T; Mugitani A; Ando M; Komatsu N
Hematology; 2024 Dec; 29(1):2340149. PubMed ID: 38626148
[TBL] [Abstract][Full Text] [Related]
2. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives.
Hasselbalch HC; Bjørn ME
Mediators Inflamm; 2015; 2015():102476. PubMed ID: 26604428
[TBL] [Abstract][Full Text] [Related]
3. Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.
Hasselbalch HC; Junker P; Skov V; Kjær L; Knudsen TA; Larsen MK; Holmström MO; Andersen MH; Jensen C; Karsdal MA; Willumsen N
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686599
[TBL] [Abstract][Full Text] [Related]
4. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
Lewandowski K; Kanduła Z; Gniot M; Paczkowska E; Nawrocka PM; Wojtaszewska M; Janowski M; Mariak M; Handschuh L; Kozlowski P
Ann Hematol; 2022 Dec; 101(12):2665-2677. PubMed ID: 36266510
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
6. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
7. Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers.
Liisborg C; Skov V; Kjær L; Hasselbalch HC; Lykke Sørensen T
PLoS One; 2022; 17(6):e0269960. PubMed ID: 35709177
[TBL] [Abstract][Full Text] [Related]
8. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
Liisborg C
Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of IL-4, IL-13 and IL-33 in patients with age-related macular degeneration and myeloproliferative neoplasms.
Gotfredsen K; Liisborg C; Skov V; Kjær L; Hasselbalch HC; Sørensen TL
Sci Rep; 2023 Mar; 13(1):4077. PubMed ID: 36906669
[TBL] [Abstract][Full Text] [Related]
10. Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.
Bak M; Sørensen TL; Flachs EM; Zwisler AD; Juel K; Frederiksen H; Hasselbalch HC
JAMA Ophthalmol; 2017 Aug; 135(8):835-843. PubMed ID: 28655032
[TBL] [Abstract][Full Text] [Related]
11. Patients with MPNs and retinal drusen show signs of complement system dysregulation and a high degree of chronic low-grade inflammation.
Liisborg C; Skov V; Kjær L; Hasselbalch HC; Sørensen TL
EClinicalMedicine; 2022 Jan; 43():101248. PubMed ID: 35128362
[TBL] [Abstract][Full Text] [Related]
12. Retinal drusen in patients with chronic myeloproliferative blood cancers are associated with an increased proportion of senescent T cells and signs of an aging immune system.
Liisborg C; Skov V; Kjær L; Hasselbalch HC; Sørensen TL
Aging (Albany NY); 2021 Dec; 13(24):25763-25777. PubMed ID: 34954692
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
